Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-44991-w
Abstract: Prostate cancer (PCa) is the most common cancer amongst men. A novel androgen receptor (AR) antagonist, enzalutamide (ENZA) has recently been demonstrated to enhance the effect of radiation (XRT) by impairing the DNA damage repair… read more here.
Keywords: hormone; hormone resistant; prostate cancer; hormone sensitive ... See more keywords
Abstract P1-09-16: A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer and non-mutated BRCA
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p1-09-16
Abstract: Background: Poly (ADP-ribose) inhibitors (PARPi) are effective in patients (pts) with germline BRCA 1/2 and PALB2 mutations but have been largely ineffective as monotherpy in others. PARP interacts with, and is recruited to, DNA damage… read more here.
Keywords: cancer; phase study; astx727 plus; hormone resistant ... See more keywords
Key indicators for guiding tocilizumab therapy to prevent orbital decompression surgery in hormone-resistant dysthyroid optic neuropathy
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2025.1556742
Abstract: Introduction Tocilizumab (TCZ) has been demonstrated to be effective in treating thyroid-associated ophthalmopathy (TAO); however, its efficacy in hormone-resistant dysthyroid optic neuropathy (DON) remains unclear. This study aims to identify baseline and post-treatment indicators that… read more here.
Keywords: surgery; temporalis max; eom temporalis; hormone resistant ... See more keywords